الفهرس 
AcknowledmentsOnly 14 pages are availabe for public view
 |  | from | 92 |  |  |
| | | from | 92 | | |
Abstract
Summary and Conclusion
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide, the number of chronically infected persons worldwide may exceed 200 million, but most of them have no knowledge of their infection or of the ensuing hepatic condition
In the early years of chronic hepatitis C (CHC) management, treatment with non-peginterferons (pegINFs) without and later with ribavirin (RBV) resulted in low efficacy and was poorly tolerated.
The emergence of a new and novel treatment for CHC signals a major change in the standard of care. In addition, our understanding of the definition and benefits of effective treatment has recently expanded.
The goal of treatment in all infected individuals, regardless of which of the six major genotypes (G1-6) are present, has been and continues to be the achievement of (SVR) in which circulating HCV RNA is undetectable with the use of a highly sensitive assay following treatment. The recently published efficacy and safety of sofosbuvir (SBV)-containing regimens with ribavirin alone or with peg-interferon plus ribavirin signal a new era and a great hope in treatment of patients with CHC.
In this prospective study, conducted on 100 patients having CHC with no manifestation of cirrhosis or liver cell failure recruited from the National Center for Control of Viral Hepatitis in Assiut that is supervised by the Ministry of Health. The patients were selected according the selection criteria determined by the National Committee for Control of Viral Hepatitis (NCCVH). Those patients received sofosbuvir (Sovaldi, Gilaad, USA) based regimens.
All patients received triple therapy (Peg INF, weight based ribavirin and sofosbuvir 400 mg for three months). The laboratory investigations were ordered before starting treatment, at end of the 1stmonth, 2ndmonth, and 3rd month and after3rd month of end of treatment.
HCV RNA was negative in 92 patients (92%) at the end of treatment and 92 patients (92%) after 3 months post- treatment. It was found that only the difference in degree of fibrosis by (FIB 4) the negativity of PCR and APRI score were statistically significant before start treatment and at the end of treatment with P value 0.002 ,0.005 and0.051 respectively.
The efficacy of this triple therapy was 92% with minor side effects which was managed during treatment and no patients stopped treatment because of side effects.
Conclusion
Sofosbuvir based regimens were effective in treatment of CHC and the efficacy was 92% with minor side effects ,FIB4 score decreased after treatment this means that fibrosis improved with this treatment and with further development of sofosbuvir based regimens the hope to increase efficacy and decrease fibrosis will be raised.